Medtronic's roughly $43 billion acquisition and merger with Covidien has been widely discussed in the media for its U.S. Federal tax implications, but it's also creating a stronger leading player in one of the fastest growing device markets, according to Kalorama Information.
Stentys announced that the Self-Apposing Stent has been implanted more than 10,000 times in patients worldwide
Research and Markets has announced the addition of the "MediPoint: Nuclear Imaging - PET and SPECT Equipment - Global Analysis and Market Forecasts" report to their offering
SPONSORED CONTENT — Studycast is a comprehensive imaging workflow system that allows healthcare professionals to work ...
Volcano Corp. announced that more than 1,000 systems have been activated with its instant wave-Free Ratio (iFR) Modality software, featuring a simplified workflow and reduced need for hyperemic agents.
Biotronik announced the publication of new findings from the REPLACE Registry in Circulation: Arrhythmia and Electrophysiology. The Biotronik-sponsored REPLACE Registry was the first worldwide study to examine complications related to pacemaker or implantable cardioverter defibrillator (ICD) replacement.
Minneapolis Heart Institute Foundation (MHIF) researchers have performed two implants of the Lotus Cardiac Valve System as part of the REPRISE III clinical trial.
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
Discussions regarding late-breaking cardiovascular clinical trials among leading medical scientists are placing considerable emphasis on individualized patient care, particularly in the area of dual antiplatelet therapy, according to an analyst with research and consulting firm GlobalData.
Bayer HealthCare announced that the U.S. Food and Drug Administration (FDA) has approved Gadavist (gadobutrol) injection for use with magnetic resonance imaging (MRI) in pediatric patients less than 2 years of age, including term neonates, to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system.
A study that identifies new heart attack risk factors and supports the use of a blood test for detection in patients will be published in the AACE (American Association of Clinical Endocrinologists) Journal.
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
As many as 500,000 people in the United States have a heritable and potentially fatal heart disease called hypertrophic cardiomyopathy.
InspireMD, Inc. announced results from two important clinical trials. Thirty-day results from the MASTER II trial, which enrolled 310 of a planned 1,114 patients were presented at a major cardiology congress in Israel in December. The trial was suspended in October 2014 as a result of a corporate shift in strategy to a next-generation MGuard drug eluting stent (DES) platform. The company also announced ipsilateral diffusion weighted magnetic resonance imaging (DW-MRI) results from the CARENET Trial for the CGuard system which successfully completed enrollment in July.
Sorin Group announced U.S. Food and Drug Administration (FDA) clearance for Memo 3-D ReChord, a semi-rigid annuloplasty ring for mitral valve repair.
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
The issue of sudden cardiac death has long been a concern of heart specialists, for cardiac arrest often hits young, apparently healthy and athletic people out of the blue.

The first large-scale, multispecialty prospective clinical research trial to evaluate the use of inferior vena cava (IVC) filters and related follow-up treatment in the United States is set to enroll the first patient in spring 2015 with participation from seven filter manufacturers.
The U.S. Food and Drug Administration (FDA) has cleared Medtronic’s In.Pact Admiral drug-coated balloon (DCB) for the interventional treatment of peripheral artery disease (PAD) for the superficial femoral and popliteal arteries in the upper leg. This is the second drug-eluting balloon (DEB) cleared by the FDA, the first being C. R. Bard’s Lutonix 035 approved in November.